Scientists test drug duo to outsmart lung Cancer's resistance
NCT ID NCT03122717
Summary
This study is testing if using two drugs, osimertinib and gefitinib, together works better than one alone for people newly diagnosed with a specific type of advanced lung cancer (EGFR mutation). The main goal is to see if this combination can control the cancer for longer by trying to prevent the cancer from becoming resistant to treatment. Researchers will test two different dosing schedules to find the best and safest way to give the drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.